1. Meaning

Prescription channel exclusivity refers to an arrangement under which a pharmaceutical manufacturer, distributor, pharmacy network, hospital, insurer, pharmacy-benefit intermediary, or digital prescription platform restricts the supply, dispensing, routing, or promotion of prescription medicines to a particular channel or set of authorised intermediaries.

Examples include:

• requiring a drug manufacturer to supply only one wholesaler;
• requiring pharmacies to purchase a particular manufacturer's medicines exclusively through a designated distributor;
• preventing competing distributors from supplying a prescription medicine;
• requiring doctors or healthcare institutions to route prescriptions through a particular platform;
• requiring patients to obtain a medicine only from an affiliated pharmacy;
• giving an exclusive pharmacy network access to a medicine;
• restricting generic suppliers from reaching pharmacies or hospitals;
• making access to one pharmaceutical product conditional on purchasing another product;
• using rebates to make pharmacies obtain nearly all prescription medicines from one supplier.

The competition issue is particularly sensitive because prescription medicines involve doctors, patients, pharmacies, wholesalers, hospitals, insurers/PBMs and manufacturers, creating several potentially distinct markets.

2. Why prescription-channel exclusivity raises competition concerns

Exclusivity can have legitimate commercial purposes. A manufacturer may want:

• reliable distribution;
• quality control;
• cold-chain management;
• inventory monitoring;
• anti-counterfeit protection;
• pharmacovigilance;
• predictable supply;
• specialised handling of biologics;
• reduced distribution costs.

However, exclusivity may become problematic when it prevents rival products or distributors from reaching patients.

The basic competitive mechanism is:

Exclusive agreement

↓

Rival distributor/pharmacy/platform loses access

↓

Rival products become harder to obtain

↓

Entry or expansion becomes more difficult

↓

Competitive constraints weaken

↓

Potentially higher prices / reduced choice / reduced innovation

This is especially important for prescription drugs because patients often cannot freely substitute between products without a physician's prescription or clinical approval.

3. Indian competition-law framework

For an India-focused analysis, prescription-channel exclusivity can principally engage Sections 3 and 4 of the Competition Act, 2002.

Section 3

Section 3 addresses agreements that cause or are likely to cause an appreciable adverse effect on competition (AAEC).

Vertical arrangements are particularly relevant where exclusivity exists between:

• manufacturer and distributor;
• manufacturer and pharmacy;
• distributor and pharmacy;
• pharmaceutical company and hospital;
• pharmaceutical company and digital prescription platform.

Potential categories include:

• exclusive supply agreements;
• exclusive distribution arrangements;
• refusal to deal;
• tying;
• market allocation.

Section 3(4) is therefore particularly important.

4. Section 4 — Abuse of dominance

Where the undertaking imposing exclusivity is dominant, Section 4 becomes important.

Potential theories include:

Limiting market access

A dominant pharmaceutical company might prevent competing manufacturers or distributors from accessing pharmacies.

Discriminatory conditions

A dominant supplier might offer favourable supply terms only to pharmacies agreeing to exclusivity.

Leveraging

A company could use dominance in one market to strengthen its position in another.

Refusal to deal

A dominant manufacturer could refuse to supply a distributor because that distributor also carries competing products.

Tying

Access to a desirable prescription medicine might be conditioned upon purchasing another product.

5. Relevant markets

Prescription-channel exclusivity requires careful market definition.

Potential relevant markets include:

• manufacture and supply of a particular prescription drug;
• supply of generic medicines;
• wholesale distribution of pharmaceutical products;
• retail pharmacy services;
• hospital pharmacy services;
• online pharmacy services;
• prescription-routing platforms;
• electronic prescription services;
• pharmacy-benefit management services.

A medicine may have a relatively narrow therapeutic market because physicians and patients may regard different drugs as poor substitutes.

The distribution market can therefore be analysed separately from the pharmaceutical product market.

6. Important Indian case law

Case 1 — Santuka Associates Pvt. Ltd. v. All India Organisation of Chemists & Druggists (AIOCD)

This is one of the most important Indian authorities for pharmaceutical distribution restrictions.

The dispute concerned restrictions imposed by chemists' and druggists' associations on the appointment of stockists.

The CCI found that association guidelines restricting the appointment of stockists and requiring mechanisms such as NOCs/LOCs could restrict competition in pharmaceutical distribution. The case illustrates how collective control over access to the distribution channel can constitute a serious competition concern.

The Supreme Court subsequently considered the statutory position concerning the relevant conduct.

Principle

A distribution system cannot be used collectively by competitors to control:

• who may become a stockist;
• how many stockists may operate;
• which distributors receive pharmaceutical products.

The case is highly relevant to prescription-channel exclusivity because control over distribution can indirectly determine which medicines reach pharmacies and ultimately patients.

The CCI materials describe restrictions on stockist appointments as limiting the number of market participants and controlling pharmaceutical supply.

Case 2 — Peeveear Medical Agencies v. AIOCD & Ors.

This case concerned restrictions imposed in the pharmaceutical distribution chain involving AIOCD and regional chemists' associations.

The complainant operated in wholesale drug distribution and alleged restrictions concerning pharmaceutical distribution and stockist arrangements.

The case illustrates the importance of distinguishing:

legitimate manufacturer-distributor arrangements

from

collective restrictions imposed by competing distributors or trade associations.

Principle

An individual manufacturer may have legitimate reasons for selecting particular distributors. However, competing distributors acting collectively cannot use association power to prevent pharmaceutical companies from independently choosing their distribution channels.

This distinction is central to prescription-channel exclusivity.

Case 3 — M/s Royal Agency v. Chemists & Druggists Association, Goa & Ors., Case No. 63 of 2013

This case is particularly relevant to refusal to supply.

The informant alleged that pharmaceutical supplies were stopped after it refused to become a member of the relevant association and failed to obtain an NOC.

The allegation was that the arrangement restricted the supply and market for medicines and amounted to refusal to deal.

The CCI considered the interaction between:

• pharmaceutical manufacturer;
• stockist;
• trade association;
• distributor.

Principle

A pharmaceutical distributor's access cannot legitimately be made dependent upon compliance with collectively imposed association requirements where those requirements restrict market access.

This is particularly relevant where an "exclusive channel" is created indirectly through collective refusal to supply.

Case 4 — M/s Santuka Associates Pvt. Ltd. v. AIOCD & Ors.

The case also provides an important illustration of the relationship between distribution restrictions and Section 3.

The CCI examined arrangements under which stockists could be restricted through association guidelines.

The relevant concern was not simply that one pharmaceutical company selected one distributor. Rather, the concern was that an association representing market participants could collectively control distribution access.

Principle

There is an important distinction between:

individual vertical exclusivity

and

collective exclusion imposed by competitors.

The latter presents a much stronger competition concern because it can function as a cartel-like barrier to entry.

The CCI's materials describe AIOCD-related conduct involving NOCs, restrictions on stockist appointments and boycott mechanisms.

Case 5 — Kailash Gupta v. All India Organisation of Chemists & Druggists & Ors., Case No. 06 of 2012

This long-running pharmaceutical-distribution matter involved allegations concerning:

• NOCs/LOCs;
• stockist appointments;
• product information service requirements;
• trade margins;
• boycott practices;
• supply restrictions.

The DG had previously found adverse evidence relating to the operation of the arrangements. However, in its 29 June 2026 order, the CCI closed the proceedings, finding that the evidence did not establish a continuing contravention because the historical MoUs had been discontinued and sufficient evidence of continuation of the alleged practices was not demonstrated.

Importance

This case is important because it demonstrates that:

historical restrictive conduct does not automatically establish a current competition-law violation.

For prescription-channel exclusivity, the authority must establish the relevant conduct and its continuation/effect during the period under investigation.

Case 6 — Manoj Hirasingh Pardeshi v. Gilead Sciences Inc.

This pharmaceutical case concerned licensing arrangements involving APIs and restrictions on pharmaceutical companies' ability to obtain supplies from alternative sources.

The allegations included:

• exclusive supply arrangements;
• exclusive distribution provisions;
• territorial restrictions;
• restrictions on alternative API suppliers;
• tying of API supply to pharmaceutical production.

Principle

Exclusivity can raise Section 3 concerns when it prevents pharmaceutical manufacturers from obtaining inputs from alternative sources or restricts the markets in which medicines can be supplied.

Although this is primarily an upstream pharmaceutical-supply case rather than a retail prescription-channel case, its principles are relevant to vertical exclusivity throughout the pharmaceutical chain.

Case 7 — Becton Dickinson India Pvt. Ltd. / Max Super Specialty Hospital

This matter involved allegations concerning supply of medical products to a hospital's in-house pharmacy.

The informant alleged that Becton Dickinson and Max Hospital had arrangements affecting the sale of particular medical products.

The investigation examined whether the parties had an exclusive supply arrangement. The DG found that the relevant products were supplied through different distributors and that there was no exclusive agreement of the type alleged. The CCI accepted the finding that Section 3(3) was not contravened.

Importance

This provides an important negative example:

The mere fact that a hospital pharmacy obtains products from a particular supplier does not establish exclusivity.

There must be evidence of an agreement or conduct that actually restricts competitive supply.

7. International authority — Surescripts litigation

The US FTC v. Surescripts proceedings provide an especially useful modern example because the conduct involves the electronic prescription-routing channel.

Surescripts operates technology connecting prescribers and pharmacies.

The FTC alleged that contractual discounts and incentives encouraged customers to use Surescripts for all or nearly all transactions, making the arrangements effectively exclusive and making entry by competing prescription-routing platforms more difficult.

Why it matters

This illustrates how exclusivity can exist without an express contractual statement saying:

"You must use our platform exclusively."

Instead:

High share-of-wallet requirement

financial incentives

=

de facto exclusivity

This is highly relevant to modern electronic prescription ecosystems.

8. Exclusive distribution and pharmaceutical markets

Exclusive distribution is not automatically unlawful.

Suppose a pharmaceutical manufacturer appoints:

Distributor A as its exclusive distributor for northern India.

That arrangement might create efficiencies involving:

• inventory;
• transportation;
• cold-chain management;
• product tracking;
• pharmacovigilance;
• anti-counterfeit controls.

The competition analysis therefore asks whether the exclusivity forecloses a substantial portion of the market.

Relevant factors include:

• market share of the supplier;
• market coverage of the exclusivity;
• duration;
• number of competing suppliers;
• availability of alternative distributors;
• entry barriers;
• switching costs.